Sen. Sheldon Whitehouse Sells Kenvue Inc. (NYSE:KVUE) Stock

Key Points

• Sen. Sheldon Whitehouse sold between $1,001 and $15,000 of Kenvue Inc. (NYSE:KVUE) stock on August 28, according to a filing disclosed on September 3rd.
• Kenvue reported $3.84 billion in revenue for its last quarter, slightly below analysts' expectations, while earnings per share came in at $0.29, beating estimates.
• Recently, Kenvue declared a quarterly dividend of $0.2075 per share, increasing from the previous $0.21.

Senator Sheldon Whitehouse (D-Rhode Island) recently sold shares of Kenvue Inc. NYSE: KVUE. In a filing disclosed on September 03rd, the Senator disclosed that they had sold between $1,001 and $15,000 in Kenvue stock on August 28th.

Senator Sheldon Whitehouse also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Danaher NYSE: DHR on 8/28/2025.
• Sold $15,001 - $50,000 in shares of UnitedHealth Group NYSE: UNH on 8/28/2025.
• Sold $15,001 - $50,000 in shares of Lam Research NASDAQ: LRCX on 8/28/2025.
• Sold $15,001 - $50,000 in shares of NVIDIA NASDAQ: NVDA on 7/7/2025.
• Sold $15,001 - $50,000 in shares of Analog Devices NASDAQ: ADI on 7/3/2025.

Kenvue Price Performance

Shares of KVUE stock traded down $1.91 on Friday, reaching $18.64. The company's stock had a trading volume of 135,326,130 shares, compared to its average volume of 13,801,933. The company has a quick ratio of 0.68, a current ratio of 0.98 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a 12-month low of $17.15 and a 12-month high of $25.17. The company has a market capitalization of $35.76 billion, a P/E ratio of 25.18, a PEG ratio of 2.67 and a beta of 0.83. The stock's 50 day simple moving average is $21.37 and its 200-day simple moving average is $22.38.

Kenvue (NYSE:KVUE - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported $0.29 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.28 by $0.01. Kenvue had a return on equity of 20.06% and a net margin of 9.37%.The company had revenue of $3.84 billion for the quarter, compared to the consensus estimate of $3.94 billion. During the same quarter last year, the business posted $0.32 earnings per share. The firm's revenue was down 4.0% compared to the same quarter last year. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. As a group, equities analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, August 27th. Investors of record on Wednesday, August 13th were given a $0.2075 dividend. This represents a $0.83 dividend on an annualized basis and a dividend yield of 4.5%. This is a boost from Kenvue's previous quarterly dividend of $0.21. The ex-dividend date was Wednesday, August 13th. Kenvue's dividend payout ratio (DPR) is 112.16%.

Analyst Upgrades and Downgrades

KVUE has been the topic of a number of research reports. Royal Bank Of Canada lowered their price target on Kenvue from $24.00 to $22.00 and set a "sector perform" rating on the stock in a research report on Friday, August 8th. Zacks Research upgraded Kenvue to a "strong sell" rating in a research report on Monday, August 11th. Bank of America lowered their price target on Kenvue from $27.00 to $25.00 and set a "buy" rating on the stock in a research report on Tuesday, July 15th. Canaccord Genuity Group lowered their price target on Kenvue from $29.00 to $26.00 and set a "buy" rating on the stock in a research report on Friday, August 8th. Finally, Citigroup lowered their price target on Kenvue from $24.50 to $22.00 and set a "neutral" rating on the stock in a research report on Tuesday, July 15th. Five analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $24.38.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Pittenger & Anderson Inc. purchased a new position in shares of Kenvue in the first quarter worth about $30,000. TruNorth Capital Management LLC bought a new stake in shares of Kenvue in the first quarter worth about $36,000. Truvestments Capital LLC bought a new stake in shares of Kenvue in the first quarter worth about $37,000. Trust Co. of Vermont grew its stake in shares of Kenvue by 266.8% in the second quarter. Trust Co. of Vermont now owns 1,581 shares of the company's stock worth $33,000 after purchasing an additional 1,150 shares during the last quarter. Finally, Clal Insurance Enterprises Holdings Ltd grew its stake in shares of Kenvue by 378.5% in the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 1,627 shares of the company's stock worth $39,000 after purchasing an additional 1,287 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company's stock.

About Senator Whitehouse

Sheldon Whitehouse (Democratic Party) is a member of the U.S. Senate from Rhode Island. He assumed office on January 3, 2007. His current term ends on January 3, 2031. Whitehouse (Democratic Party) ran for re-election to the U.S. Senate to represent Rhode Island. He won in the general election on November 5, 2024.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.